Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Accepts Victory Pharma’s Anti-Nausea NDA for Review

By Pharmaceutical Processing | July 13, 2009

Victory Pharma, Inc. has announced that the FDA has acceptedfor review the New Drug Application (NDA) for Victory’s lead investigationaldrug, MGX006. If approved, MGX006 will provide patients and healthcareproviders the advantage of a proven antiemetic agent combined with aproprietary formulation ideally suited for the treatment of nausea andvomiting. “Acceptance of the MGX006 NDA is a significant milestone, it demonstratesVictory’s ability to grow its commercial portfolio via internal productdevelopment in addition to in-licensing products,” said Matt Heck, ChiefExecutive Officer of Victory. “Pending FDA approval, we are planning for afirst half of 2010 product launch, allowing Victory to further leverage its150 person field sales organization. Given many patients suffering from painalso suffer from emesis, there is a good fit between MGX006 and Victory’sgrowing, pain management franchise.” Approximately 25 million prescriptions are written annually in the U.S.for anti-emetic therapeutics. The vast majority of these prescriptions arefor traditional, oral solid drug formulations, which can be problematic amongpatients with emesis. “We believe the attributes of MGX006 will provide an important alternativefor patients suffering from nausea and vomiting of various etiologies,” saidDr. Shawn Scranton, Vice President, Scientific Operations. “We look forwardto working closely with the FDA on a timely approval.”

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE